Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | IAPP | P10997 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269457 | 0.86 | MAPT (0.43) | MAOBMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL31547780 | 0.83 | HTR2C (0.49) | MAOBMAPTHTR2BHTR1A | |
| SCHEMBL25029606 | 0.82 | HTR2A (0.58) | HTR2AHTR2BHTR1A | |
| SCHEMBL1727095 | 0.81 | ATM (0.40) | MAOBMAPTALDH1A1HTTNPC1 | |
| SCHEMBL1727808 | 0.80 | HTR2B (0.51) | MAOBHTR2B | |
| SCHEMBL1727107 | 0.80 | HTR2B (0.49) | MAOBMAPTHTR2B | |
| SCHEMBL1726678 | 0.77 | HTR2B (0.52) | MAOBHTR2B | |
| SCHEMBL1727408 | 0.76 | GFER (0.41) | MAOBMAPTHTTNPC1RAB9A | |
| SCHEMBL1726725 | 0.76 | HTR2B (0.41) | MAOBHTR2AHTR2BMAOA | |
| SCHEMBL25030184 | 0.76 | MPO (0.38) | MAOBHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100263138-A1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'OREAL S.A. (FR) | 2010-10-21 | — | — | US | claimed |
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | L'OREAL (FR) | 2004-11-25 | — | — | US | claimed |
| EP-1428510-A1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, and a heterocyclic coupler or a hydroxybenzamide ; method and use | L'OREAL (FR) | 2004-06-16 | — | — | EP | claimed |
| EP-0506549-B1 | Dyeing composition for keratinous fibers containing oxidation dye precursors and hydroxybenzofurans as couplers and dyeing process making use of such a composition | OREAL (FR) | 1995-10-18 | — | — | EP | claimed |
| US-5203875-A | Hair dyes also using ortho- and para-phenylenediamines or aminophenols; colorfastness; washfastness; perspiration resistance | L'OREAL (FR) | 1993-04-20 | — | — | US | claimed |
| WO-2023079291-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2023-05-11 | — | — | WO | disclosed |
| US-9920012-B2 | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2182914-B1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'ORÉAL (FR) | 2017-11-08 | — | — | EP | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| CN-105968049-A | Method for preparing 1-(2,6-dichlorobenzyl-3-(pyrrolidine-1-methyl)-6-aminoindazole | 深圳市茵诺圣生物科技有限公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-2175830-B1 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | ORÉAL L (FR) | 2015-09-30 | — | — | EP | disclosed |
| US-20150152063-A1 | INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-06-04 | — | — | US | disclosed |
| WO-2013185045-A1 | INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2013-12-12 | — | — | WO | disclosed |
| US-8043385-B2 | Composition oxidation colouring of keratinic fibres, containing a cationic cellulose ether, a metasilicate and oxidation dyes, method for oxidation colouring and uses thereof | L'OREAL S.A. (FR) | 2011-10-25 | — | — | US | disclosed |
| US-8002847-B2 | Composition for oxidation dyeing keratin fibres comprising a cationic cellulose ether, a weakly oxyethylenated sorbitan fatty acid ester and oxidation dyes | L 'OREAL S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20100275388-A1 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | L'OREAL S.A. (FR) | 2010-11-04 | — | — | US | disclosed |
| US-20100263138-A1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'OREAL S.A. (FR) | 2010-10-21 | — | — | US | disclosed |
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | L'OREAL (FR) | 2004-11-25 | — | — | US | disclosed |
| EP-1428510-A1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, and a heterocyclic coupler or a hydroxybenzamide ; method and use | L'OREAL (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-5203875-A | Hair dyes also using ortho- and para-phenylenediamines or aminophenols; colorfastness; washfastness; perspiration resistance | L'OREAL (FR) | 1993-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152063-A1 | INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | MAPKAPK2 3619/4885MAOB 2328/4885MAPT 3020/4885 |
| US-20100275388-A1 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | KRT18, KRTCAP2, FASN | MAPKAPK2 2005/4885MAOB 1389/4885MAPT 687/4885 |
| US-20100263138-A1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | KRT18, TUBB3, VIM | MAPKAPK2 1193/4885MAOB 607/4885MAPT 522/4885 |
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | KRT18, CDC73, PYCR1 | MAPKAPK2 3975/4885MAOB 1272/4885MAPT 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.